In clinical trials, since CD19 targeted CAR-T cells showed excellent efficacy in the treatments of patients with hematologic malignancies, the FDA has approved CD19 CAR-T cells as new therapies for non-Hodgkin's lymphoma and chemotherapy-refractory/relapsed acute lymphoblastic leukemia treatments [7]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.